130 related articles for article (PubMed ID: 27520724)
21. Polypeptide-based combination of paclitaxel and cisplatin for enhanced chemotherapy efficacy and reduced side-effects.
Song W; Tang Z; Li M; Lv S; Sun H; Deng M; Liu H; Chen X
Acta Biomater; 2014 Mar; 10(3):1392-402. PubMed ID: 24316362
[TBL] [Abstract][Full Text] [Related]
22. TAK-441, a novel investigational smoothened antagonist, delays castration-resistant progression in prostate cancer by disrupting paracrine hedgehog signaling.
Ibuki N; Ghaffari M; Pandey M; Iu I; Fazli L; Kashiwagi M; Tojo H; Nakanishi O; Gleave ME; Cox ME
Int J Cancer; 2013 Oct; 133(8):1955-66. PubMed ID: 23564295
[TBL] [Abstract][Full Text] [Related]
23. Codelivery of small molecule hedgehog inhibitor and miRNA for treating pancreatic cancer.
Kumar V; Mondal G; Slavik P; Rachagani S; Batra SK; Mahato RI
Mol Pharm; 2015 Apr; 12(4):1289-98. PubMed ID: 25679326
[TBL] [Abstract][Full Text] [Related]
24. Stromal Modulation Reverses Primary Resistance to Immune Checkpoint Blockade in Pancreatic Cancer.
Zhao J; Xiao Z; Li T; Chen H; Yuan Y; Wang YA; Hsiao CH; Chow DS; Overwijk WW; Li C
ACS Nano; 2018 Oct; 12(10):9881-9893. PubMed ID: 30231203
[TBL] [Abstract][Full Text] [Related]
25. A paclitaxel-loaded recombinant polypeptide nanoparticle outperforms Abraxane in multiple murine cancer models.
Bhattacharyya J; Bellucci JJ; Weitzhandler I; McDaniel JR; Spasojevic I; Li X; Lin CC; Chi JT; Chilkoti A
Nat Commun; 2015 Aug; 6():7939. PubMed ID: 26239362
[TBL] [Abstract][Full Text] [Related]
26. Novel oral administrated paclitaxel micelles with enhanced bioavailability and antitumor efficacy for resistant breast cancer.
Zhang T; Luo J; Fu Y; Li H; Ding R; Gong T; Zhang Z
Colloids Surf B Biointerfaces; 2017 Feb; 150():89-97. PubMed ID: 27898360
[TBL] [Abstract][Full Text] [Related]
27. Biodegradable mixed MPEG-SS-2SA/TPGS micelles for triggered intracellular release of paclitaxel and reversing multidrug resistance.
Dong K; Yan Y; Wang P; Shi X; Zhang L; Wang K; Xing J; Dong Y
Int J Nanomedicine; 2016; 11():5109-5123. PubMed ID: 27785018
[TBL] [Abstract][Full Text] [Related]
28. Dehydroascorbic Acids-modified Polymer Micelles Target Cancer Cells to Enhance Anti-tumor Efficacy of Paclitaxel.
Pei X; Luo F; Zhang J; Chen W; Jiang C; Liu J
Sci Rep; 2017 Apr; 7(1):975. PubMed ID: 28428562
[TBL] [Abstract][Full Text] [Related]
29. The eradication of breast cancer and cancer stem cells using octreotide modified paclitaxel active targeting micelles and salinomycin passive targeting micelles.
Zhang Y; Zhang H; Wang X; Wang J; Zhang X; Zhang Q
Biomaterials; 2012 Jan; 33(2):679-91. PubMed ID: 22019123
[TBL] [Abstract][Full Text] [Related]
30. In vivo comparative study of distinct polymeric architectures bearing a combination of paclitaxel and doxorubicin at a synergistic ratio.
Baabur-Cohen H; Vossen LI; Krüger HR; Eldar-Boock A; Yeini E; Landa-Rouben N; Tiram G; Wedepohl S; Markovsky E; Leor J; Calderón M; Satchi-Fainaro R
J Control Release; 2017 Jul; 257():118-131. PubMed ID: 27374630
[TBL] [Abstract][Full Text] [Related]
31. CD44-Targeted Polymer-Paclitaxel Conjugates to Control the Spread and Growth of Metastatic Tumors.
Zaiden M; Rütter M; Shpirt L; Ventura Y; Feinshtein V; David A
Mol Pharm; 2018 Sep; 15(9):3690-3699. PubMed ID: 29957956
[TBL] [Abstract][Full Text] [Related]
32. Chemosensitizing indomethacin-conjugated dextran-based micelles for effective delivery of paclitaxel in resistant breast cancer therapy.
Ji W; Wang B; Fan Q; Xu C; He Y; Chen Y
PLoS One; 2017; 12(7):e0180037. PubMed ID: 28686704
[TBL] [Abstract][Full Text] [Related]
33. PEG-derivatized octacosanol as micellar carrier for paclitaxel delivery.
Chu B; Qu Y; Huang Y; Zhang L; Chen X; Long C; He Y; Ou C; Qian Z
Int J Pharm; 2016 Mar; 500(1-2):345-59. PubMed ID: 26794876
[TBL] [Abstract][Full Text] [Related]
34. Enhanced antiproliferative and apoptosis effect of paclitaxel-loaded polymeric micelles against non-small cell lung cancers.
Zhang XY; Zhang YD
Tumour Biol; 2015 Jul; 36(7):4949-59. PubMed ID: 25702089
[TBL] [Abstract][Full Text] [Related]
35. Hyaluronic acid functional amphipathic and redox-responsive polymer particles for the co-delivery of doxorubicin and cyclopamine to eradicate breast cancer cells and cancer stem cells.
Hu K; Zhou H; Liu Y; Liu Z; Liu J; Tang J; Li J; Zhang J; Sheng W; Zhao Y; Wu Y; Chen C
Nanoscale; 2015 May; 7(18):8607-18. PubMed ID: 25898852
[TBL] [Abstract][Full Text] [Related]
36. PEG-PE-based micelles co-loaded with paclitaxel and cyclosporine A or loaded with paclitaxel and targeted by anticancer antibody overcome drug resistance in cancer cells.
Sarisozen C; Vural I; Levchenko T; Hincal AA; Torchilin VP
Drug Deliv; 2012 May; 19(4):169-76. PubMed ID: 22506922
[TBL] [Abstract][Full Text] [Related]
37. The use of cholesterol-containing biodegradable block copolymers to exploit hydrophobic interactions for the delivery of anticancer drugs.
Lee AL; Venkataraman S; Sirat SB; Gao S; Hedrick JL; Yang YY
Biomaterials; 2012 Feb; 33(6):1921-8. PubMed ID: 22137125
[TBL] [Abstract][Full Text] [Related]
38. Dual thermoresponsive and pH-responsive self-assembled micellar nanogel for anticancer drug delivery.
Chen D; Yu H; Sun K; Liu W; Wang H
Drug Deliv; 2014 Jun; 21(4):258-64. PubMed ID: 24102086
[TBL] [Abstract][Full Text] [Related]
39. Systemic delivery of micelles loading with paclitaxel using N-succinyl-palmitoyl-chitosan decorated with cRGDyK peptide to inhibit non-small-cell lung cancer.
Yuan ZQ; Li JZ; Liu Y; Chen WL; Yang SD; Zhang CG; Zhu WJ; Zhou XF; Liu C; Zhang XN
Int J Pharm; 2015 Aug; 492(1-2):141-51. PubMed ID: 26188316
[TBL] [Abstract][Full Text] [Related]
40. Novel self-associating poly(ethylene oxide)-b-poly(epsilon-caprolactone) based drug conjugates and nano-containers for paclitaxel delivery.
Shahin M; Lavasanifar A
Int J Pharm; 2010 Apr; 389(1-2):213-22. PubMed ID: 20080163
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
